Estradiol regulates estrogen receptor mRNA stability.
Previous studies suggest that post-transcriptional events play an important role in estrogen-induced loss of estrogen receptor expression. The present study shows that treatment of MCF-7 cells with estradiol resulted in a six-fold decrease in estrogen receptor mRNA half-life from 4 h in control cells to 40 min in estradiol treated cells. To determine the role of protein synthesis in the regulation of estrogen receptor mRNA stability, several translational inhibitors were utilized. Pactamycin and puromycin, which prevent ribosome association with mRNA, inhibited the effect of estradiol on receptor mRNA stability, whereas cycloheximide, which has no effect on ribosome association with mRNA, had no effect on estradiol regulation of estrogen receptor mRNA stability. In control cells, the total cellular content of estrogen receptor mRNA was associated with high molecular weight polyribosomes. Treatment with estradiol resulted in a 70% decrease in estrogen receptor mRNA associated with polyribosomes but had no effect on the polyribosome distribution of estrogen receptor mRNA. In an in vitro degradation assay, polyribosomes isolated from estradiol-treated cells degraded ER mRNA faster than polyribosomes isolated from control cells. The nuclease activity associated with the polysome fraction appeared to be Mg2+ independent and inhibited by RNasin. Freeze-thawing and heating at 90 degrees C for 10 min resulted in the loss of nuclease activity. These studies suggest that an estrogen-regulated nuclease activity associated with ribosomes alters the stability of estrogen receptor mRNA.
Saceda
M
M
Department of Biochemistry and Molecular Biology, Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, DC 20007, USA.
Lindsey
R K
RK
Solomon
H
H
Angeloni
S V
SV
Martin
M B
MB
D001943:Breast Neoplasms; D002499:Centrifugation, Density Gradient; D003513:Cycloheximide / Q000494:pharmacology; D004355:Drug Stability; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology*; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008274:Magnesium / Q000494:pharmacology; D010142:Pactamycin / Q000494:pharmacology; D010926:Placental Hormones / Q000494:pharmacology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D011691:Puromycin / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000235:genetics*; D012260:Ribonucleases / Q000037:antagonists & inhibitors / Q000378:metabolism; D012270:Ribosomes / Q000378:metabolism / Q000648:ultrastructure; D014407:Tumor Cells, Cultured
D004791:Enzyme Inhibitors; D010926:Placental Hormones; D011500:Protein Synthesis Inhibitors; D012333:RNA, Messenger; D011960:Receptors, Estrogen; C022052:placental ribonuclease inhibitor; D010142:Pactamycin; D011691:Puromycin; D004958:Estradiol; D003513:Cycloheximide; D012260:Ribonucleases; D008274:Magnesium